Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)

PaperCitations, authors & open-access status

Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 237 citations, 2022 year and closed oa status.